Enhanced synergy has been observed in several tumor types, including melanoma (vaccine + pembrolizumab), prostate cancer (PROSTVAC + nivolumab), cervical cancer (PDS0101 + PDS01ADC + PD-L1/TGF-β inhibition, MEDI0457 + durvalumab, ISA101 + nivolumab), head and neck cancer (anti-MAGED4B/FJX1 + anti-PD-1) and supports further development of engineered combination strategies [18, 35–39]. Here, CD274 is linked to neoplasm.